SCHEMBL4901741

SCHEMBL4901741

O=C(O)c1ccc(-c2cn(Cc3ccccc3)c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Cl)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.37
KLKB1 P03952 1/20 0.37
KLK1 P06870 1/20 0.37
PTGER4 P35408 3/20 0.35
CCR2 P41597 3/20 0.34
MMP13 P45452 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
MTHFD2 P13995 1/20 0.34
EPHX2 P34913 1/20 0.34
PPARG P37231 1/20 0.34
ALDH1A1 P00352 2/20 0.34
RHEB Q15382 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
MAPK10 P53779 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899991 0.91 KLKB1 (0.39) L3MBTL1KLKB1KLK1MMP13ALDH1A1
SCHEMBL4898669 0.90 ALDH1A1 (0.39) L3MBTL1MMP13SLC22A8ALDH1A1RHEB
SCHEMBL4895489 0.90 ALDH1A1 (0.39) L3MBTL1MMP13SLC22A8ALDH1A1RHEB
SCHEMBL4901306 0.88 ALDH1A1 (0.39) L3MBTL1MMP13SLC22A8ALDH1A1RHEB
SCHEMBL4889733 0.84 ALDH1A1 (0.38) L3MBTL1MMP13ALDH1A1RHEBCYP1A2
SCHEMBL4901737 0.83 PTPN1 (0.46) L3MBTL1PTGER4CCR2MTHFD2EPHX2
SCHEMBL4898625 0.83 KDM4E (0.37) PTGER4ALDH1A1RHEBMAPK10
SCHEMBL4901331 0.82 MAPK10 (0.42) L3MBTL1MMP13ALDH1A1MAPK10
SCHEMBL4903709 0.82 MAPK10 (0.42) L3MBTL1MMP13ALDH1A1MAPK10
SCHEMBL4901582 0.81 F2RL3 (0.43) L3MBTL1ALDH1A1TSHRMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS L3MBTL1 3294/4885KLKB1 2407/4885KLK1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.